SEARCH

SEARCH BY CITATION

References

  • 1
    Wolf JS Jr, Hubbard H, Faraday MM, Forrest JB. Clinical practice guidelines to inform evidence-based clinical practice. World J Urol 2011; 29: 303309
  • 2
    Ransohoff DF, Pignone M, Sox HC. How to decide whether a clinical practice guideline is trustworthy. JAMA 2013; 309: 139140
  • 3
    Faraday M, Hubbard H, Kosiak B, Dmochowski R. Staying at the cutting edge: a review and analysis of evidence reporting and grading; the recommendations of the American Urological Association. BJU Int 2009; 104: 294297
  • 4
    Moyer VA, U.S. Preventive Services Task Force. Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2012; 157: 120134
  • 5
    Greene KL, Albertsen PC, Babaian RJ et al. Prostate specific antigen best practice statement: 2009 update. J Urol 2009; 182: 22322241
  • 6
    Carter HB, Albertsen PC, Barry MJ et al. Early detection of prostate cancer: AUA guideline. J Urol 2013; In press. doi: 10.1016/j.juro.2013.04.119 [Epub ahead of print]
  • 7
    Li J, Djenaba JA, Soman A, Rim SH, Master VA. Recent trends in prostate cancer incidence by age, cancer stage, and grade, the United States, 2001–2007. Prostate Cancer 2012; 2012: 691380
  • 8
    Brawley OW. Prostate cancer epidemiology in the United States. World J Urol 2012; 30: 195200
  • 9
    Andriole GL, Grubb RL, Buys SS et al. Mortality results from a randomized prostate-cancer screening trial. N Engl J Med 2009; 360: 13101319
  • 10
    Schroder FH, Hugosson J, Roobol MJ et al. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 2009; 360: 13201328
  • 11
    Howard K, Barratt A, Mann GJ, Patel MI. A model of prostate-specific antigen screening outcomes for low- to high-risk men: information to support informed choices. Arch Intern Med 2009; 169: 16031610
  • 12
    Lilja H, Cronin AM, Dahlin A et al. Prediction of significant prostate cancer diagnosed 20 to 30 years later with a single measure of prostate-specific antigen at or before age 50. Cancer 2011; 117: 12101219
  • 13
    The Surveillance, Epidemiology, and End Results (SEER) Program of the National Cancer Institute. Fast Stats. Available at: http://seer.cancer.gov/faststats. Accessed 3 June 2013
  • 14
    Savage CJ, Lilja H, Cronin AM, Ulmert D, Vickers AJ. Empirical estimates of the lead time distribution for prostate cancer based on two independent representative cohorts of men not subject to prostate-specific antigen screening. Cancer Epidemiol Biomarkers Prev 2010; 19: 12011207
  • 15
    Schroder FH, Hugosson J, Roobol MJ et al. Prostate-cancer mortality at 11 years of follow-up. N Engl J Med 2012; 366: 981990
  • 16
    Hugosson J, Carlsson S, Aus G et al. Mortality results from the Göteborg randomised population-based prostate-cancer screening trial. Lancet Oncol 2010; 11: 725732
  • 17
    GLOBOCAN: prostate cancer incidence and mortality worldwide in 2008: summary. GLOBOCAN (IARC), Section of Cancer Information 2008. Available at: http://globocan.iarc.fr/factsheets/cancers/prostate.asp. Accessed June 2013
  • 18
    Kilpeläinen TP, Tammela TL, Malila N et al. Prostate cancer mortality in the Finnish randomized screening trial. J Natl Cancer Inst 2013; 105: 719725
  • 19
    Carter HB, Epstein JI, Chan DW, Fozard JL, Pearson JD. Recommended prostate-specific antigen testing intervals for detection of curable prostate cancer. JAMA 1997; 277: 14561460
  • 20
    Gulati R, Gore JL, Etzioni R. Comparative effectiveness of alternative prostate-specific antigen – based prostate cancer screening strategies: model estimates of potential benefits and harms. Ann Intern Med 2013; 158: 145153
  • 21
    Fang J, Metter EJ, Landis P, Chan DW, Morrell CH, Carter HB. Low levels of prostate specific antigen (PSA) predict the long term risk of prostate cancer: results from the Baltimore Longitudinal Study of Aging. Urology 2001; 58: 411416
  • 22
    Aus G, Damber JE, Khatami A, Lilja H, Stranne J, Hugosson J. Individualized screening interval for prostate cancer based on prostate-specific antigen level: results of a prospective, randomized, population-based study. Arch Intern Med 2005; 165: 18571861
  • 23
    Vickers AJ, Cronin AM, Björk T et al. Prostate specific antigen concentration at age 60 and death or metastasis from prostate cancer: case-control study. BMJ 2010; 341: c4521
  • 24
    Gulati R, Wever EM, Tsodikov A et al. What if I don't treat my PSA-detected prostate cancer? Answers from three natural history models. Cancer Epidemiol Biomarkers Prev 2011; 20: 740750
  • 25
    Wilt TJ, Brawer MK, Jones KM et al.; Prostate Cancer Intervention versus Observation Trial (PIVOT) Study Group. Radical prostatectomy versus observation for localized prostate cancer. N Engl J Med 2012; 367: 203213
  • 26
    Bill-Axelson A, Holmberg L, Ruutu M et al. Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med 2011; 364: 17081717
  • 27
    Popiolek M, Rider JR, Andren O et al. Natural history of early, localized prostate cancer: a final report from three decades of follow-up. Eur Urol 2013; 63: 428435
  • 28
    Schaeffer EM, Carter HB, Kettermann A et al. Prostate specific antigen testing among the elderly – when to stop? J Urol 2009; 181: 16061614
  • 29
    Brawley OW. Guideline promises to end twenty-year war over mass screening for prostate cancer. Cancer Lett 2013; 39: 1